Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment
Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate
Mofetil following single course of Rituximab in maintaining remission over 12 months among
Children with frequently-relapsing or steroid-dependent nephrotic syndrome
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Shanghai Children's Hospital Shanghai Children's Medical Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine